Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI

Ling Xu, Jianyu Weng, Xin Huang, Chengwu Zeng, Shaohua Chen, Suxia Geng, Lijian Yang, Suijing Wu, Suming Huang, Xin Du, Yangqiu Li

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The outcome for T-cell acute lymphoblastic leukemia (T-ALL) in relapse after hematopoietic stem cell transplantation (HSCT) is quite poor, while, both donor lymphocytes infusion (DLI) and adoptively infusion of γδ T cells in leukemia patients after HSCT have demonstrated good results in prolonging survival time of patients. Here, we reported a T-ALL case who experienced three relapses and received HSCT and DLI with an overall survival (OS) time lasting for more than seven years. Based on our previous identification of a leukemic and reactive clone in this patient, continual γδ T cell repertoire monitoring affirmed that the same Vd5 leukemic clone existed in most samples from the patient, particularly including a sample taken at the time of the third T-ALL relapse, while it could not be detected in the donor sample. In addition, an identical Vd4 monoclonal T cell that proliferated in the recipient for several years was confirmed to come from the donor graft, and its expression level significantly increased in third leukemia recurrence. These results indicate that clonally expanded Vd4 T cells may represent a reconstituted γδ T cell repertoire after HSCT, which also hints to a relatively better outcome for this case. Based on this case study, we recommend DLI should be as a treatment strategy for patients who achieve CR or relapse from HSCT. Moreover, dynamically monitoring the TCR repertoire in patients who receive HSCT will benefit in supervising of malignant clone evolution and residue, identifying T cell clones mediate anti-infection, GvHD or GvL.

Original languageEnglish (US)
Pages (from-to)42943-42952
Number of pages10
JournalOncotarget
Volume7
Issue number28
DOIs
StatePublished - Jan 1 2016

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Hematopoietic Stem Cell Transplantation
Clone Cells
Tissue Donors
Lymphocytes
T-Lymphocytes
Survival
Recurrence
T-Cell Leukemia
Leukemia
Transplants
Infection

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Xu, Ling ; Weng, Jianyu ; Huang, Xin ; Zeng, Chengwu ; Chen, Shaohua ; Geng, Suxia ; Yang, Lijian ; Wu, Suijing ; Huang, Suming ; Du, Xin ; Li, Yangqiu. / Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI. In: Oncotarget. 2016 ; Vol. 7, No. 28. pp. 42943-42952.
@article{cc144f0e851543c78d84f416bc5a9c90,
title = "Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI",
abstract = "The outcome for T-cell acute lymphoblastic leukemia (T-ALL) in relapse after hematopoietic stem cell transplantation (HSCT) is quite poor, while, both donor lymphocytes infusion (DLI) and adoptively infusion of γδ T cells in leukemia patients after HSCT have demonstrated good results in prolonging survival time of patients. Here, we reported a T-ALL case who experienced three relapses and received HSCT and DLI with an overall survival (OS) time lasting for more than seven years. Based on our previous identification of a leukemic and reactive clone in this patient, continual γδ T cell repertoire monitoring affirmed that the same Vd5 leukemic clone existed in most samples from the patient, particularly including a sample taken at the time of the third T-ALL relapse, while it could not be detected in the donor sample. In addition, an identical Vd4 monoclonal T cell that proliferated in the recipient for several years was confirmed to come from the donor graft, and its expression level significantly increased in third leukemia recurrence. These results indicate that clonally expanded Vd4 T cells may represent a reconstituted γδ T cell repertoire after HSCT, which also hints to a relatively better outcome for this case. Based on this case study, we recommend DLI should be as a treatment strategy for patients who achieve CR or relapse from HSCT. Moreover, dynamically monitoring the TCR repertoire in patients who receive HSCT will benefit in supervising of malignant clone evolution and residue, identifying T cell clones mediate anti-infection, GvHD or GvL.",
author = "Ling Xu and Jianyu Weng and Xin Huang and Chengwu Zeng and Shaohua Chen and Suxia Geng and Lijian Yang and Suijing Wu and Suming Huang and Xin Du and Yangqiu Li",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.10260",
language = "English (US)",
volume = "7",
pages = "42943--42952",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "28",

}

Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI. / Xu, Ling; Weng, Jianyu; Huang, Xin; Zeng, Chengwu; Chen, Shaohua; Geng, Suxia; Yang, Lijian; Wu, Suijing; Huang, Suming; Du, Xin; Li, Yangqiu.

In: Oncotarget, Vol. 7, No. 28, 01.01.2016, p. 42943-42952.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI

AU - Xu, Ling

AU - Weng, Jianyu

AU - Huang, Xin

AU - Zeng, Chengwu

AU - Chen, Shaohua

AU - Geng, Suxia

AU - Yang, Lijian

AU - Wu, Suijing

AU - Huang, Suming

AU - Du, Xin

AU - Li, Yangqiu

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The outcome for T-cell acute lymphoblastic leukemia (T-ALL) in relapse after hematopoietic stem cell transplantation (HSCT) is quite poor, while, both donor lymphocytes infusion (DLI) and adoptively infusion of γδ T cells in leukemia patients after HSCT have demonstrated good results in prolonging survival time of patients. Here, we reported a T-ALL case who experienced three relapses and received HSCT and DLI with an overall survival (OS) time lasting for more than seven years. Based on our previous identification of a leukemic and reactive clone in this patient, continual γδ T cell repertoire monitoring affirmed that the same Vd5 leukemic clone existed in most samples from the patient, particularly including a sample taken at the time of the third T-ALL relapse, while it could not be detected in the donor sample. In addition, an identical Vd4 monoclonal T cell that proliferated in the recipient for several years was confirmed to come from the donor graft, and its expression level significantly increased in third leukemia recurrence. These results indicate that clonally expanded Vd4 T cells may represent a reconstituted γδ T cell repertoire after HSCT, which also hints to a relatively better outcome for this case. Based on this case study, we recommend DLI should be as a treatment strategy for patients who achieve CR or relapse from HSCT. Moreover, dynamically monitoring the TCR repertoire in patients who receive HSCT will benefit in supervising of malignant clone evolution and residue, identifying T cell clones mediate anti-infection, GvHD or GvL.

AB - The outcome for T-cell acute lymphoblastic leukemia (T-ALL) in relapse after hematopoietic stem cell transplantation (HSCT) is quite poor, while, both donor lymphocytes infusion (DLI) and adoptively infusion of γδ T cells in leukemia patients after HSCT have demonstrated good results in prolonging survival time of patients. Here, we reported a T-ALL case who experienced three relapses and received HSCT and DLI with an overall survival (OS) time lasting for more than seven years. Based on our previous identification of a leukemic and reactive clone in this patient, continual γδ T cell repertoire monitoring affirmed that the same Vd5 leukemic clone existed in most samples from the patient, particularly including a sample taken at the time of the third T-ALL relapse, while it could not be detected in the donor sample. In addition, an identical Vd4 monoclonal T cell that proliferated in the recipient for several years was confirmed to come from the donor graft, and its expression level significantly increased in third leukemia recurrence. These results indicate that clonally expanded Vd4 T cells may represent a reconstituted γδ T cell repertoire after HSCT, which also hints to a relatively better outcome for this case. Based on this case study, we recommend DLI should be as a treatment strategy for patients who achieve CR or relapse from HSCT. Moreover, dynamically monitoring the TCR repertoire in patients who receive HSCT will benefit in supervising of malignant clone evolution and residue, identifying T cell clones mediate anti-infection, GvHD or GvL.

UR - http://www.scopus.com/inward/record.url?scp=84978765453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978765453&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10260

DO - 10.18632/oncotarget.10260

M3 - Article

C2 - 27356746

AN - SCOPUS:84978765453

VL - 7

SP - 42943

EP - 42952

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 28

ER -